Arterial occlusion sites on magnetic resonance angiography influence the efficacy of intravenous low-dose (0·6mg/kg) alteplase therapy for ischaemic stroke

International Journal of Stroke

Volumn 4, Issue 6, 2009, Pages 425-431

  Nakashima, T ^a   Toyoda, K ^a   Koga, M ^a   Matsuoka, H ^a   Nagatsuka, K ^a   Takada, T ^a   Naritomi, H ^a   Minematsu, K ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Carotid artery occlusion; Cerebral infarction; Stroke outcome; Thrombolysis; Tissue plasminogen activator

Indexed keywords

PLASMINOGEN ACTIVATOR; TISSUE PLASMINOGEN ACTIVATOR;

AGED; ARTICLE; BRAIN; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CAROTID ARTERY OBSTRUCTION; COMPUTER ASSISTED TOMOGRAPHY; DIFFUSION WEIGHTED IMAGING; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; METHODOLOGY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROSPECTIVE STUDY; RISK; RISK FACTOR; STROKE; TREATMENT OUTCOME;

AGED; ARTERIAL OCCLUSIVE DISEASES; BRAIN; BRAIN ISCHEMIA; CAROTID STENOSIS; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; INTRACRANIAL HEMORRHAGES; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PLASMINOGEN ACTIVATORS; PROSPECTIVE STUDIES; RISK FACTORS; STROKE; TISSUE PLASMINOGEN ACTIVATOR; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 70350527974     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1111/j.1747-4949.2009.00347.x     Document Type: Article

References (36)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333:1581-7.
2. Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA 2000; 283:1145-50.
3. Hill MD, Buchan AM, Canadian Alteplase for Stroke Effectiveness Study (CASES) Investigators. Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study. CMAJ 2005; 172:1307-12.
4. Wahlgren N, Ahmed N, Dávalos A et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007; 369:275-82.
5. Bateman BT, Schumacher HC, Boden-Albala B et al. Factors associated with in-hospital mortality after administration of thrombolysis in acute ischemic stroke patients: an analysis of the nationwide inpatient sample 1999 to 2002. Stroke 2006; 37:440-6.
6. Shen AY, Yao JF, Brar SS, Jorgensen MB, Chen W. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol 2007; 50:309-15.
7. Yamaguchi T, Kikuchi H, Hayakawa T, Japanese Thrombolysis Study Group. Clinical efficacy and safety of intravenous tissue plasminogen activator in acute embolic stroke: a randomized, double-blind, dose comparison study of duteplase; in Yamaguchi T, Mori E, Minematsu K, Del Zoppo GJ (eds): Thrombolytic Therapy in Acute Ischemic Stroke III. Tokyo, Japan: Springer-Verlag, 1995: 223-9.
8. Yamaguchi T, Mori E, Minematsu K et al. Alteplase at 0·6mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteprase Clinical Trial. Stroke 2006; 37:1810-5.
9. Shinohara Y, Yamaguchi T. Outline of the Japanese Guidelines for the Management of Stroke 2004 and subsequent revision. Int J Stroke 2008; 3:55-62.
10. Guideline Committee for Intravenous rt-PA (alteplase) in Acute Ischemic Stroke. Guidelines for intravenous application of rt-PA (alteplase). Jpn J Stroke 2005; 26:327-54.
11. Shinohara Y. The changing face of the burden of stroke in Japan. Int J Stroke 2007; 2:133-5.
12. Köhrmann M, Jüttler E, Fiebach JB et al. MRI versus CT-based thrombolysis treatment within and beyond the 3h time window after stroke onset: a cohort study. Lancet Neurol 2006; 5:661-7.
13. Schellinger PD, Thomalla G, Fiehler J et al. MRI-based and CT-based thrombolytic therapy in acute stroke within and beyond established time windows: an analysis of 1210 patients. Stroke 2007; 38:2640-5.
14. Barber PA, Demchuk AM, Zhang J, Buchan AM, for the ASPECTS Study Group. Validity and reliability of a semiquantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. Lancet 2000; 355:1670-4.
15. Hirano T, Yonehara T, Inatomi Y, Hashimoto Y, Uchino M. Presence of early ischemic changes on computed tomography depends on severity and the duration of hypoperfusion: a single photon emission-computed tomographic study. Stroke 2005; 36:2601-8.
16. Barber PA, Hill MD, Eliasziw M et al. Imaging of the brain in acute ischaemic stroke: comparison of computed tomography and magnetic resonance diffusion-weighted imaging. J Neurol Neurosurg Psychiatry 2005; 76:1528-33.
17. Rubiera M, Ribo M, Delgado-Mederos R et al. Tandem internal carotid artery/middle cerebral artery occlusion: an independent predictor of poor outcome after systemic thrombolysis. Stroke 2006; 37:2301-5.
18. Saqqur M, Uchino K, Demchuk AM et al. Site of arterial occlusion identified by transcranial Doppler predicts the response to intravenous thrombolysis for stroke. Stroke 2007; 38:948-54.
19. Itoh T, Matsumoto M, Handa N et al. Rate of successful recording of blood flow signals in the middle cerebral artery using transcranial Doppler sonography. Stroke 1993; 24:1192-5.
20. Edaravone Acute Infarction Study Group. Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis 2003; 15:222-9.
21. Haley EC Jr, Lewandowski C, Tilley BC. Myths regarding the NINDS rt-PA stroke trial: setting the record straight. Ann Emerg Med 1997; 30:676-82.
22. Brown DL, Johnston KC, Wagner DP, Haley EC Jr Predicting major neurological improvement with intravenous recombinant tissue plasminogen activator treatment of stroke. Stroke 2004; 35:147-50.
23. Adams HP Jr, Bendixen BH, Kappelle LJ et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. Stroke 1993; 24:35-41.
24. Hacke W, Donnan G, Fieschi C et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004; 363:768-74.
25. Mori E, Yoneda Y, Tabuchi M et al. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology 1992; 42:976-82.
26. Jensen O, Von Kummer R, Forsting M, Hacke W, Sartor K. Thrombolytic therapy in acute occlusion of the intracranial internal carotid artery bifurcation. Am J Neuroradiol 1995; 16:1977-86.
27. Del Zoppo G, Poeck K, Pessin MS et al. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol 1992; 32:78-86.
28. Linfante I, Llinas RH, Selim M et al. Clinical and vascular outcome in internal carotid artery versus middle cerebral artery occlusions after intravenous tissue plasminogen activator. Stroke 2002; 33:2066-71.
29. Kanal E, Barkovich AJ, Bell C et al. ACR guidance document for safe MR practices: 2007. Am J Roentgenol 2007; 188:1447-74.
30. Lansberg MG, Albers GW, Beaulieu C, Marks MP. Comparison of diffusion-weighted MRI and CT in acute stroke. Neurology 2000; 54:1557-61.
31. Fiebach JB, Schellinger PD, Jansen O et al. CT and diffusion-weighted MR imaging in randomized order: diffusion-weighted imaging results in higher accuracy and lower interrater variability in the diagnosis of hyperacute ischemic stroke. Stroke 2002; 33:2206-10.
32. Kimura K, Iguchi Y, Shibazaki K et al. Large ischemic lesions on diffusion-weighted imaging done before intravenous tissue plasminogen activator thrombolysis predicts a poor outcome in patients with acute stroke. Stroke 2008; 39:2388-91.
33. Kimura K, Kazui S, Minematsu K, Yamaguchi T, Japan Multicenter Stroke Investigator's Collaboration. Analysis of 16, 922 patients with acute ischemic stroke and transient ischemic attack in Japan. A hospital-based prospective registration study. Cerebrovasc Dis 2004; 18:47-56.
34. Hsia AW, Sachdev HS, Tomlinson J, Hamilton SA, Tong DC Efficacy of IV tissue plasminogen activator in acute stroke: does stroke subtype really matter? Neurology. 2003; 61:71-5.
35. Flint AC, Duckwiler GR, Budzik RF, Liebeskind DS, Smith WS, MERCI and Multi MERCI Writing Committee. Mechanical thrombectomy of intracranial internal carotid occlusion: pooled results of the MERCI and Multi MERCI Part I trials. Stroke 2007; 38:1274-80.
36. Khatri P, Hill MD, Palesch YY et al. Methodology of the Interventional Management of Stroke III Trial. Int J Stroke 2008; 3:130-7.